Researchers develop a new PET radiotracer that can quickly identify life-threatening atherosclerotic plaques by detecting inflammation. This breakthrough has the potential to prevent heart attacks and strokes by allowing for early treatment of atherosclerosis.
Researchers have found that somatostatin receptor sst2 antagonist tracers can target a greater number of sst2 sites in non-NET tumors than agonists. The study shows high binding of the antagonist in 12 breast cancers, all renal cell carcinomas, and 5 medullary thyroid cancers, while agonist binding was low or absent in these cases.
A new gallium-68 labeled peptide BBN-RGD agent has been developed to target both gastrin-releasing peptide receptor and integrin αvβ3, providing dual-receptor targeting and advantages over single-receptor targeting. The agent has shown safety and effectiveness in detecting primary and metastatic prostate cancer lesions.
Researchers argue that the linear no-threshold hypothesis, which suggests all radiation is harmful, is inaccurate and has led to widespread fear of low-dose radiation. Studies show that low doses stimulate protective responses, reducing cancer risk rather than increasing it.
A German multicenter study confirms the efficacy and safety of Lu-177-PSMA-617 radioligand therapy for metastatic castration-resistant prostate cancer, demonstrating a positive response rate of 45% and manageable side effects. The treatment offers an additional option for end-stage patients with high response rates and low toxicity.
Researchers developed low-cost 3D printed organ models of varying size and shape to aid in determining optimal dosing for individual patients. The study demonstrates the potential of 3D printing technology for clinical prototyping, particularly in quantitative SPECT/CT imaging.
A novel imaging agent, Zr-89-Df-IAB2M, has been shown to detect metastasis of prostate cancer in both bone and soft tissue lesions with high accuracy. The agent targets PSMA on the exterior of prostate cancer cells, allowing for faster and more accurate detection than conventional methods.
Researchers have successfully used PET imaging to visualize cardiac amyloidosis, a condition characterized by abnormal protein deposits in the heart. The study showed that F-18-florbetaben PET imaging can accurately identify and differentiate between cardiac amyloidosis and hypertensive heart disease.
The study demonstrates the effectiveness of activity-based probes in detecting early signs of atherosclerosis. By targeting cysteine cathepsins, the probes image activated macrophage populations using optical and PET/CT methods, providing real-time monitoring of disease progression and therapeutic responses.
Researchers developed a new radiotracer that safely and effectively maps sentinel lymph nodes in breast cancer patients. The study demonstrated the tracer's ability to provide clear SLN imaging with high detection rates.
The SNMMI-TS awarded Lynne Roy, Crystal Botkin, David Campbell, Marcia Hess Smith, Deborah Gibbs, Dmitry D. Beyder, and Aaron Scott for their exceptional contributions to the field of nuclear medicine technology, including education, service, and leadership.
SNMMI recognized Peter Herscovitch and Satoshi Minoshima for their contributions to the field of nuclear medicine through various awards. Dominique Delbeke received the Presidential Distinguished Educator Award for her work as editor of The Journal of Nuclear Medicine.
A new PET/MRI imaging test has been shown to improve the detection of significant prostate cancer, surpassing current multi-parametric MRI methods. The test's addition of molecular imaging based on F-18-choline positron emission tomography (PET) significantly improves the identification of clinically significant cancers.
A novel PET imaging study reveals a significant correlation between increased tau and decreased metabolic activity in the brains of living Alzheimer's patients, indicating clear signs of neurodegeneration. The study measures amyloid plaques, tau tangles, and metabolic activity using three different radiotracers.
A new study by the Society of Nuclear Medicine and Molecular Imaging shows that PET/CT imaging using prostate-specific membrane antigen leads to highly accurate tumor detection and delineation, with a 67% accuracy rate.
A novel CT-based calculation method, SULps, accurately measures lean body mass using computed tomography, leading to more precise PET imaging results. This improvement enables better staging of disease and therapy monitoring in cancer patients.
The novel portable diagnostic tool offers a multi-dimensional look at the body by combining optical and gamma imaging, allowing physicians to visualize molecular data alongside surface organ images. Clinical pilot studies have shown promising results in imaging lymphatic and thyroid tissue, as well as tear ducts.
Researchers used PET and SPECT to tailor radionuclide treatment for neuroendocrine cancer patients, reducing the risk of toxicity. The study showed that personalized dosimetry led to a significant alteration in radiotherapy doses, with some patients receiving reduced or increased doses.
A new PET study reveals that tau protein tangles in the brain may be driving the neurodegeneration behind Alzheimer's disease. The research found a significant correlation between increased tau and decreased metabolic activity in the brain, suggesting that tau imaging could be used to detect neuronal injury earlier than amyloid imaging.
Researchers used FDG-PET imaging to monitor atezolizumab, an immune checkpoint inhibitor, in NSCLC patients. The study found that higher baseline tumor volumes were predictive of reduced patient survival, and further increase in tumor volume after treatment was associated with decreased survival.
The Education and Research Foundation for Nuclear Medicine and Molecular Imaging honored Dr. H. William Strauss with the 2016 Benedict Cassen Prize for his seminal studies in cardiovascular nuclear medicine. This award recognizes his work that has greatly advanced nuclear medicine science and had a high clinical impact.
A genetic blood test called NETest measures specific genes in the blood that define and predict responsiveness to PRRT. The test was found to be more than 90% accurate in predicting therapy response and non-response, with 73% of low-grade tumors responding to treatment.
Ross McDougall, a renowned Stanford professor, has been honored with the 2016 Georg Charles de Hevesy Nuclear Pioneer Award for his groundbreaking work in nuclear medicine. With over 160 peer-reviewed publications and three textbooks on thyroid disease, he has made significant contributions to advancing the field of nuclear medicine.
Peter S. Conti, MD, PhD, receives the prestigious Paul C. Aebersold Award for his groundbreaking work in developing novel diagnostic imaging agents for oncology applications. His research focuses on PET imaging and gene expression, advancing the field of nuclear medicine and molecular imaging.
Researchers developed PET tracers that can visualize inflammatory disease and evaluate next-generation MS therapies. The study found that the compounds could detect an increase in S1P1 expression in animals with an inflammatory response, suggesting a promising approach for imaging MS and other inflammatory diseases.
A recent study using PET/CT imaging found that the brains of recovering alcoholics have adapted to chemical dependency by significantly hindering metabotropic glutamate receptor subtype 5 (mGluR5) receptors, reducing cravings. This discovery could lead to new targeted drugs to limit receptor activity in patients at risk of relapse.
Researchers developed pretargeted radioimmunotherapy, combining an anti-GPA33 antibody with radionuclide agents to deliver radiation directly to tumors. In mouse models, the technique achieved complete remission of colorectal cancer without collateral toxicity.
A recent study found that sodium fluoride (Na-F-18) positron emission tomography/computed tomography (NaF-PET/CT) accurately detects bone metastases in patients with advanced prostate cancer. The imaging modality also correlates clearly with clinical outcomes and patient survival over time.
A recent study found that Ga-68 DOTATATE PET/CT scans are superior to In-111 pentetreotide scans in detecting neuroendocrine tumors, leading to improved treatment management and patient outcomes. The imaging method demonstrated no significant toxicity, lower radiation exposure, and increased accuracy.
Researchers used SPECT-MRI fusion to assess sentinel lymph nodes in early-stage cervical cancer patients, finding that it could identify metastases with high accuracy. This non-invasive approach may reduce the need for surgical removal of lymph nodes and improve patient outcomes.
Researchers found that genetics play a major role in the bilateral parietal lobes and left temporal lobe, while environment dominates other brain regions. This study provides insights into how nature and environment interact to shape our brains, potentially informing the development of neurological and psychiatric disorders.
A recent study shows that a PET/CT scan using F-18-DCFBC is significantly more effective in detecting metastatic prostate cancer than other detection methods. The radiotracer targets prostate-specific membrane antigen, which is expressed in the majority of prostate cancers and associated with metastatic spread.
A recent study found that PET/CT and whole-body MRI detect extraskeletal disease, changing cancer management. Combined administration of F-18 sodium fluoride (NaF) and F-18 fluorodeoxyglucose (FDG) in a single PET/CT scan showed higher sensitivity and accuracy than alternative methods.
A new imaging agent, Ga-68 PSMA, significantly improved detection of early recurrent prostate cancer in a study published in The Journal of Nuclear Medicine. The agent was found to detect sites of possible recurrence in 50% of patients with low PSA levels, compared to only 12.5% for another widely used agent.
Researchers developed a molecular imaging biomarker that detects fast-growing primary prostate cancer and distinguishes it from benign prostate lesions. The new PSMA-based PET imaging technique was more specific than MR imaging for detecting clinically significant high-grade prostate cancer lesions.
A new molecular imaging agent has been developed to detect prostate cancer that has spread to other tissues. The agent targets the PSMA enzyme, which is associated with prostate cancer, and has shown high accuracy in detecting disease sites, including those not identified by conventional methods.
A specialized PET tracer has been developed to visualize the function of nerve cells that lead to neuronal loss and cognitive decline in neurodegenerative diseases. The tracer binds to a transporter of the neurotransmitter acetylcholine, allowing for the quantification of cholinergic neuron loss and its effects on cognition.
Researchers have developed three new MRI agents that successfully target the prostate-specific membrane antigen (PSMA) biomarker in multiple cancers. PSMA is found in both primary and metastatic prostate tumors, as well as in newly developing blood vessels of many non-prostate cancers.
The hybrid scanner combines conventional MRI, hyperpolarized MRI, positron imaging, luminescence imaging, and fluorescence microscopy to provide high-resolution multimodal intra-vital imaging. This allows researchers to study tumor biology and develop targeted therapies by analyzing the co-registration of multiple imaging data lines.
Researchers have developed a cloud-based software that analyzes and standardizes PET imaging data, allowing for earlier and more accurate diagnoses of Alzheimer's disease. The program uses machine learning to compare patients' scans with normal and abnormal scans, providing consistent results and quantifying PET data accurately.
A new technique combines dynamic PET imaging with parametric tumor mapping to detect tumors and metastases throughout the body, providing quantitative evaluation and improved contrast. This method has the potential to be used for early diagnosis and more accurate prognosis of various cancers.
Researchers used PET/CT with Ga-68 DOTATOC to detect primary tumors in patients with metastatic neuroendocrine cancer. The study found that 28% of patients underwent a major change in cancer management due to the imaging technique.
Research shows amyloid PET scans improve diagnosis and treatment outcomes for Alzheimer's patients, especially when used after an indeterminate FDG-PET scan. The study found that 17% of patients who received an amyloid scan experienced statistically significant improvements in cognition over a two-year follow-up.
Researchers developed PSMA-617, a theranostic drug that detects prostate cancer and targets enzyme on cancer cells. The technology shows substantial reduction in radiotracer uptake and significant decrease in PSMA in blood after therapy, indicating positive response.
A new theranostic agent, I-124 PEG-AVP0458, has shown promise in targeting both ovarian and prostate cancer cells for imaging and treatment. The drug compound attaches itself to the targeted tumor sites via positron emission tomography (PET) scanners, enabling personalized cancer therapy.
A novel PET technique tracks microglial activation in response to endotoxin, shedding light on neuroinflammatory diseases like Alzheimer's and depression. The study's findings could lead to new drug treatments by targeting immune dysfunction.
A new study found that PET/CT scans are highly sensitive for detecting relapsed non-Hodgkin lymphoma, with a sensitivity rate of 95.1%. This breakthrough has significant implications for patient care, as early diagnosis can lead to improved treatment outcomes and longer survival rates.
A new molecular imaging scan detects dangerous protein deposits in the heart, significantly increasing cardiac risk. The scan uses a widely available agent to assess amyloid buildup and predict future heart attacks.
A novel radionuclide drug, PSMA-617, has been developed to target prostate-specific membrane antigen (PSMA) on prostate cancer cells, allowing for personalized diagnosis and therapy. The drug showed promising results in a human clinical trial, with effective imaging and therapeutic effects.
Scientists have developed a novel PET tracer that can pinpoint thrombi throughout the body with over 97% accuracy. The tracer, Cu-64 FBP8, targets fibrin in blood clots and reflects thrombus age, enabling clinicians to choose more effective treatments.